PRIMARY STUDY
Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn’s Disease
Key Findings: This mouse model of inflammatory bowel disease (IBD) and Crohn's Disease (CD) identified cannabinoid 2 receptors (CB2R) in abundance on immune cells, especially CD4+T. Targeting this mechanism of inflammation may lead to future therapeutic treatments to reduce the inflammation associated with IBD.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Germany, United States
Year of Pub: 2017
Cannabinoids Studied: Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Endocannabinoid (unspecified), Other Related Compounds, Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR 55, TRPV1, GPCR, TRPs
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
Citation: Leinwand KL, et al. Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn's Disease. J Crohns Colitis. 2017; 11:1369-1380. doi: 10.1093/ecco-jcc/jjx096
Authors: Leinwand KL, Jones AA, Huang RH, Jedlicka P, Kao DJ, de Zoeten EF, Ghosh S, Moaddel R, Wehkamp J, Ostaff MJ, Bader J, Aherne CM, Collins CB
